With unique experience under our life sciences umbrella, we are a trusted, single-source partner supporting therapeutics from discovery to commercial supply to tackle devastating diseases and improve patient lives. We provide our customers the innovation, speed, and scalability needed across every stage of the therapeutics journey to provide medicines to the millions of patients lacking sufficient treatment options.
Biopharmaceutical CDMO
Cell culture solutions
iPS cell services and research products
CRO services
Lab / diagnostic reagents and specialty chemicals
Advanced R&D
1. Put Our People First
We’re built for people. By ensuring every employee finds meaning in their daily job, we release true passion and spark, something you recognize and feel when working with us.
2. Transformative Science and Innovation
We power innovation through our ability to fuse deep bioproduction expertise — spanning cells, cell culture solutions, and process development — with Fujifilm’s core strengths in AI and sensing.
3. Unprecedented Delivery
We operate a global network of manufacturing and technology centers across locations in the US, UK, Denmark, and Japan — delivering products where and when partners need them.
FUJIFILM Biosciences
FUJIFILM Biotechnologies
FUJIFILM Biotechnologies California
FUJIFILM Cellular Dynamics
FUJIFILM Toyama Chemical
FUJIFILM Wako Pure Chemical
Kojo — has a dual meaning in Japanese: “factory” and “improvement.”
X — represents both the power of being location-agnostic and the exponential impact we seek to transform the industry.
Taken together, kojoX™ is how we’re building a global CDMO network across scales, technologies, and locations with a harmonization level that has never been seen before in the pharmaceutical industry.
Rather than building each site as a unique facility, kojoX™ introduces a standardized approach to facility design and process operations. This gives us true supply agility, a flexibility that allows us to adapt to new products quickly, while giving us the ability to transfer products to and from anywhere in our global network.
This plug-and-play harmonization enables seamless technology transfer, faster regulatory filings, and more flexible capacity deployment. This in turn reduces the time and complexity traditionally associated with scaling biopharmaceutical manufacturing, allowing us to deliver important medicines to patients around the world more quickly.
We have process and development scientists within each life science company (FUJIFILM Biosciences, FUJIFILM Cellular Dynamics, Inc, FUJIFILM Wako Pure Chemical, FUJIFILM Toyama Chemical) and 500+ process scientists across FUJIFILM Biotechnologies’ CDMO sites (USA, United Kingdom, and Denmark).
Positioned closer to our customers, these sites drive bioprocessing improvements and innovate alongside our customers to address challenges in real time. This approach not only advances manufacturing innovation but also accelerates the delivery of solutions where they matter most.
The scalable ApolloX™ platform is designed for quality and speed of delivery of monoclonal antibodies (mAbs) and a diverse range of CHO-expressed molecules, including bispecific antibody formats, Fc-fusion proteins, and non-Fc containing recombinant proteins.
The MaruX™ platform radically reimagines continuous manufacturing of recombinant proteins by automating and integrating both upstream and downstream processes. MaruX™, which offers single-use perfusion bioreactors for high-density cultures at the 500 L to 2,000 L scale, uses an intensified, consecutive-batch end-to-end processing approach that boasts advanced buffer management, streamlined scale-up and scale-out capabilities, improved raw material efficiency and costs, while delivering unparalleled quality for our partners and patients.
Paveway PLUS™ is our proprietary microbial expression and strain development solution that has been developed for E. coli fermentation across early discovery, pre-clinical, and scale-up phases. Modular, high-throughput workflows enable rapid lead-strain selection in as little as four weeks, with product-quality metrics integrated throughout the process.
ShunzymeX™ is our precision purification technology designed to simplify downstream processing of complex biologics. The technology addresses some of the inherent challenges due to diversity of biologics, including variability in size and sequence.
The Oceo Rover™ is the first fully automated, on-demand single-use hydration system for media feeds and buffers. It replaces traditional powder hydration in stirred tanks with a single, programmable unit that delivers fast, consistent, ready-to-use solutions for both upstream and downstream processes with unmatched flexibility and scalability.
Combining biomechanics and machine learning, we are developing AI-powered capabilities to predict production outcomes based on culture conditions. During production, this technology helps minimize variation in quality and yield from batch-to-batch and site-to-site, facilitating smooth product transfer between sites.